Rate My Professor Brent Palmer

Brent Palmer, PhD, is an Associate Professor of Medicine in the Division of Allergy and Clinical Immunology at the University of Colorado Anschutz Medical Campus. As a Medicine faculty member specializing in Allergy and Clinical Immunology, he earned his BS and PhD from Colorado State University and an MS from California State University Chico. He directs the ClinImmune Flow Cytometry and Bioarchiving Facility and the Allergy and Clinical Immunology Flow Cytometry Laboratory, leveraging over 30 years of experience in flow cytometry, including generation and analysis of complex multi-color flow cytometry and CyTOF data, as well as experimental validation of microbe:metabolite:immune phenotype relationships using bacterial species or communities. Palmer also serves on the faculty of the Microbiology PhD program.

His research examines interactions between commensal microbiota and the mucosal immune system in the gut and lung, focusing on their impact on HIV disease progression, T cell function, immune dysfunction, gut microbiome alterations in HIV-positive individuals, antiretroviral treatment effects on immunity and microbiome composition in rural and urban populations, inflammation-associated microbiomes in postacute sequelae of SARS-CoV-2, and diet influences on metabolic health in HIV patients with specific microbiomes. He has published over 85 papers in clinical immunology and host-microbe interactions. Key publications include "IL-37 is a fundamental inhibitor of innate immunity" (Nature Immunology, 2010), "Negative Immune Regulator Tim-3 Is Overexpressed on T Cells in Hepatitis C Virus Infection and Its Blockade Rescues Dysfunctional CD4+ and CD8+ T Cells" (Journal of Virology, 2009), "Alterations in the gut microbiota associated with HIV-1 infection" (Cell Host & Microbe, 2013), "Gut microbiome composition influences immunologic alterations in the blood and gut of HIV-positive and HIV-negative men who have sex with men" (Frontiers in Immunology, 2025), and "Inflammation-associated gut microbiome in postacute sequelae of SARS-CoV-2 points towards new therapeutic targets" (Gut, 2024).